Advertisement

Role of Antimicrobial Stewardship Programs in Decreasing Hospital-Associated Clostridium difficile Infections

  • Doaa M. Aljefri
  • Alyssa B. Christensen
  • Amanda K. Gibson
  • Michael Postelnick
Antimicrobial Stewardship (A Pakyz, Section Editor)
  • 30 Downloads
Part of the following topical collections:
  1. Topical Collection on Antimicrobial Stewardship

Opinion statement

Purpose of review

To provide a review of literature that discusses some of the most successful antimicrobial stewardship interventions reported across institutions worldwide in response to increased Clostridium difficile infection (CDI) rates.

Recent findings

Although many different types of antimicrobial reduction practices have been proven effective, differences in resources across varying sizes of institutions may make some interventions more attainable than other. Regardless of available resources, an initial assessment of the correlation of positive laboratory tests to clinical disease is necessary to quantify the true burden of hospital-onset CDIs (HO-CDI). Infection prevention programs, in conjunction with antimicrobial reduction interventions, and the appropriate identification of patients to undergo laboratory testing, are key components of a HO-CDI reduction program.

Summary

Clostridium difficile is an important cause of serious healthcare-associated infections (HAIs), causing adverse consequences for patients including, but not limited to, increased length of hospital stay, healthcare costs, and mortality. Since the early 2000s, there has been a notable increase in CDI. Antimicrobial stewardship programs (ASPs) have responded to this public health threat with a number of different strategies including antimicrobial use reduction, education, appropriate testing, and multiple other interventions. Along with providing a literature review on ASP interventions to address the CDI threat, we describe our experience in successfully reducing HO-CDI at Northwestern Memorial Hospital with the use of multiple interventions.

Keywords

C. difficile Clostridium difficile infection Hospital-onset Clostridium difficile infection Antimicrobial stewardship 

Notes

Compliance with Ethical Standards

Conflict of Interest

Doaa M. Aljefri declares that she has no conflict of interest.

Alyssa B. Christensen declares that she has no conflict of interest.

Amanda K. Gibson declares that she has no conflict of interest.

Michael Postelnick declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Lessa FC, Winston LG, McDonald LC, Emerging Infections Program CdST. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(24):2369–70.  https://doi.org/10.1056/NEJMc1505190.PubMedGoogle Scholar
  2. 2.
    Miller M, Gravel D, Mulvey M, Taylor G, Boyd D, Simor A, et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis. 2010;50(2):194–201.  https://doi.org/10.1086/649213.CrossRefPubMedGoogle Scholar
  3. 3.
    Hsu J, Abad C, Dinh M, Safdar N. Prevention of endemic healthcare-associated Clostridium difficile infection: reviewing the evidence. Am J Gastroenterol. 2010;105(11):2327–39; quiz 40.  https://doi.org/10.1038/ajg.2010.254.
  4. 4.
    • Kuntz JL, Smith DH, Petrik AF, Yang X, Thorp ML, Barton T, et al. Predicting the risk of Clostridium difficile infection upon admission: a score to identify patients for antimicrobial stewardship efforts. Perm J. 2016;20(1):20–5.  https://doi.org/10.7812/TPP/15-049. To identify patients at risk of C. difficile infection, the study investigators developed a risk score tool that can be used by healthcare providers to determine who would benefit from an extensive antibiotic review. The risk score accurately predicted 6-month risk for C. difficile infection using patients’ preadmission characteristics.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44(2):159–77.  https://doi.org/10.1086/510393.CrossRefPubMedGoogle Scholar
  6. 6.
    • Feazel LM, Malhotra A, Perencevich EN, Kaboli P, Diekema DJ, Schweizer ML. Effect of antibiotic stewardship programmes on Clostridium difficile incidence: a systematic review and meta-analysis. J Antimicrob Chemother. 2014;69:1748–54.  https://doi.org/10.1093/jac/dku046. A meta-analysis of 16 articles (1997–2012), mostly European in origin, discussed different Antimicrobial Stewardship Program interventions including restrictive, formulary removal, persuasive and post-prescriptive. All of the interventions had a protective benefit against C. difficile infection except for persuasion.CrossRefPubMedGoogle Scholar
  7. 7.
    Karanika S, Paudel S, Grigoras C, Kalbasi A, Mylonakis E. Systematic review and meta-analysis of clinical and economic outcomes from the implementation of hospital-based antimicrobial stewardship programs. Antimicrob Agents Chemother. 2016;60(8):4840–52.  https://doi.org/10.1128/AAC.00825-16.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Brown KA, Khanafer N, Daneman N, Fisman DN. Meta-analysis of antibiotics and the risk of community-associated Clostridium difficile infection. Antimicrob Agents Chemother. 2013;57:2326–32.  https://doi.org/10.1128/AAC.02176-12.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    DiDiodato G, McArthur L. Evaluating the effectiveness of an antimicrobial stewardship program on reducing the incidence rate of healthcare-associated Clostridium difficile infection: a non-randomized, stepped wedge, single-site, Observational Study. PLoS One. 2016;11(6):e0157671.  https://doi.org/10.1371/journal.pone.0157671.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Malani AN, Richards PG, Kapila S, Otto MH, Czerwinski J, Singal B. Clinical and economic outcomes from a community hospital’s antimicrobial stewardship program. Am J Infect Control. 2013;41:145–8.  https://doi.org/10.1016/j.ajic.2012.02.021.CrossRefPubMedGoogle Scholar
  11. 11.
    Elligsen M, Walker SA, Pinto R, Simor A, Mubareka S, Rachlis A, et al. Audit and feedback to reduce broad-spectrum antibiotic use among intensive care unit patients: a controlled interrupted time series analysis. Infect Control Hosp Epidemiol. 2012;33(4):354–61.  https://doi.org/10.1086/664757.CrossRefPubMedGoogle Scholar
  12. 12.
    Amer MR, Akhras NS, Mahmood WA, Al-Jazairi AS. Antimicrobial stewardship program implementation in a medical intensive care unit at a tertiary care hospital in Saudi Arabia. Ann Saudi Med. 2013;33(6):547–54.  https://doi.org/10.5144/0256-4947.2013.547.CrossRefPubMedGoogle Scholar
  13. 13.
    • Lawes T, Lopez-Lozano JM, Nebot CA, et al. Effect of a national 4C antibiotic stewardship intervention on the clinical and molecular epidemiology of Clostridium difficile infections in a region of Scotland: a non-linear time-series analysis. Lancet Infect Dis. 2017;17:194–206.  https://doi.org/10.1016/S1473-3099(16)30397-8. The Antibiotic Stewardship Program intervention of restricting the 4Cs (ciprofloxacin/fluoroquinolones, co-amoxiclav/broad-spectrum β-lactams, clindamycin and cephalosporins) was associated with reductions in C. difficile infection rates.CrossRefPubMedGoogle Scholar
  14. 14.
    Sarma JB, Marshall B, Cleeve V, Tate D, Oswald T, Woolfrey S. Effects of fluoroquinolone restriction (from 2007 to 2012) on Clostridium difficile infections: interrupted time-series analysis. J Hosp Infect. 2015;91:74–80.  https://doi.org/10.1016/j.jhin.2015.05.013.CrossRefPubMedGoogle Scholar
  15. 15.
    Wenisch JM, Equiluz-Bruck S, Fudel M, Reiter I, Schmid A, Singer E, et al. Decreasing Clostridium difficile infections by an antimicrobial stewardship program that reduces moxifloxacin use. Antimicrob Agents Chemother. 2014;58(9):5079–83.  https://doi.org/10.1128/AAC.03006-14.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    You E, Song H, Cho J, Lee J. Reduction in the incidence of hospital-acquired Clostridium difficile infection through infection control interventions other than the restriction of antimicrobial use. Int J Infect Dis. 2014;22:9–10.  https://doi.org/10.1016/j.ijid.2014.01.011.CrossRefPubMedGoogle Scholar
  17. 17.
    Burnham CA, Carroll KC. Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev. 2013;26(3):604–30.  https://doi.org/10.1128/CMR.00016-13.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Tenover FC, Baron EJ, Peterson LR, Persing DH. Laboratory diagnosis of Clostridium difficile infection can molecular amplification methods move us out of uncertainty? J Mol Diagn. 2011;13(6):573–82.  https://doi.org/10.1016/j.jmoldx.2011.06.001.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Sharp SE, Ruden LO, Pohl JC, Hatcher PA, Jayne LM, Ivie WM. Evaluation of the C. Diff Quik Chek Complete Assay, a new glutamate dehydrogenase and A/B toxin combination lateral flow assay for use in rapid, simple diagnosis of clostridium difficile disease. J Clin Microbiol. 2010;48(6):2082–6.  https://doi.org/10.1128/JCM.00129-10.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Chapin KC, Dickenson RA, Wu F, Andrea SB. Comparison of five assays for detection of Clostridium difficile toxin. J Mol Diagn. 2011;13(4):395–400.  https://doi.org/10.1016/j.jmoldx.2011.03.004.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–55.  https://doi.org/10.1086/651706.CrossRefPubMedGoogle Scholar
  22. 22.
    Gould CV, Edwards JR, Cohen J, Bamberg WM, Clark LA, Farley MM, et al. Effect of nucleic acid amplification testing on population-based incidence rates of Clostridium difficile infection. Clin Infect Dis. 2013;57(9):1304–7.  https://doi.org/10.1093/cid/cit492.CrossRefPubMedGoogle Scholar
  23. 23.
    • Polage CR, Gyorke CE, Kennedy MA, Leslie JL, Chin DL, Wang S, et al. Overdiagnosis of Clostridium difficile infection in the Molecular Test Era. JAMA Intern Med. 2015;175(11):1792–801.  https://doi.org/10.1001/jamainternmed.2015.4114. In this prospective cohort study among 1416 hospitalized adults who were tested for C difficile infections, all patients were tested using toxin immunoassays and polymerase chain reaction (PCR) tests. All reported complications occurred in patients with positive toxin immunoassays whereas patients with positive PCR and negative toxin immunoassay tests had outcomes that were similar to patients without C. difficile infection.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Swindells J, Brenwald N, Reading N, Oppenheim B. Evaluation of diagnostic tests for Clostridium difficile infection. J Clin Microbiol. 2010;48(2):606–8.  https://doi.org/10.1128/JCM.01579-09.CrossRefPubMedGoogle Scholar
  25. 25.
    Quinn CD, Sefers SE, Babiker W, He Y, Alcabasa R, Stratton CW, et al. C. Diff Quik Chek complete enzyme immunoassay provides a reliable first-line method for detection of Clostridium difficile in stool specimens. J Clin Microbiol. 2010;48(2):603–5.  https://doi.org/10.1128/JCM.01614-09.CrossRefPubMedGoogle Scholar
  26. 26.
    • White DR, Hamilton KW, Pegues DA, Hanish A, Umscheid CA. The impact of a computerized clinical decision support tool on inappropriate Clostridium difficile testing. Infect Control Hosp Epidemiol. 2017;38(10):1204–8.  https://doi.org/10.1017/ice.2017.161. This retrospective cohort study examined the pre- versus post-implementation of a computerized clinical decision support tool among patients from three hospitals over a 2-year period. Providers were required to use the tool to order a C. difficile test, which would display a message if the patient was not severely ill or on laxatives and request a reassessment in 24 h before sending out the test. The results suggested that the tool may aid in decreasing unnecessary C. difficile testing.CrossRefPubMedGoogle Scholar
  27. 27.
    Kelly SG, Yarrington M, Zembower TR, Sutton SH, Silkaitis C, Postelnick M, et al. Inappropriate Clostridium difficile testing and consequent overtreatment and inaccurate publicly reported metrics. Infect Control Hosp Epidemiol. 2016;37(12):1395–400.  https://doi.org/10.1017/ice.2016.210.CrossRefPubMedGoogle Scholar
  28. 28.
    Debast SB, Vaessen N, Choudry A, Wiegers-Ligtvoet EA, van den Berg RJ, Kuijper EJ. Successful combat of an outbreak due to Clostridium difficile PCR ribotype 027 and recognition of specific risk factors. Clin Microbiol Infect. 2009;15(5):427–34.  https://doi.org/10.1111/j.1469-0691.2009.02713.x.CrossRefPubMedGoogle Scholar
  29. 29.
    Barbut F, Jones G, Eckert C. Epidemiology and control of Clostridium difficile infections in healthcare settings: an update. Curr Opin Infect Dis. 2011;24(4):370–6.  https://doi.org/10.1097/QCO.0b013e32834748e5.CrossRefPubMedGoogle Scholar
  30. 30.
    Dalpke AH, Hofko M, Zorn M, Zimmermann S. Evaluation of the fully automated BD MAX Cdiff and Xpert C. difficile assays for direct detection of Clostridium difficile in stool specimens. J Clin Microbiol. 2013;51(6):1906–8.  https://doi.org/10.1128/JCM.00344-13.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Christensen AB PM, Gibson AK, Martin DW, Rhodes NJ, Scheetz MH, Barr VO, Cottreau JM, Malczynski M, Qi C, Zembower TR, Bolon MK, Salim AA and Sutton, SH. Reduction of inappropriate hospital-onset Clostridium difficile testing through pre-authorization of PCR Clostridium difficile lab orders. ASM Microbe Meeting 2017.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Doaa M. Aljefri
    • 1
    • 2
  • Alyssa B. Christensen
    • 3
    • 4
  • Amanda K. Gibson
    • 5
  • Michael Postelnick
    • 1
  1. 1.Department of PharmacyNorthwestern Memorial HospitalChicagoUSA
  2. 2.King Abdulaziz Medical CityJeddahSaudi Arabia
  3. 3.College of PharmacyUniversity of Illinois at ChicagoChicagoUSA
  4. 4.Department of PharmacyOSF Saint Anthony Medical CenterRockfordUSA
  5. 5.University of Utah HealthSalt Lake CityUSA

Personalised recommendations